1. Scrip
  2. >>Business
  3. >>Commercial Strategy

Cerenis: Aspiring to Esperion?

 
• By Melanie Senior
  
Generate a summary of this article
Listen to this article
Beta

When Esperion's ex-VP chemistry and technologies Jean-Louis Dasseux, PhD co-founded Cerenis Therapeutics in March 2005, he was doubtless inspired partly by Esperion's $1.25 billion sale to Pfizer in December 2003. So were a handful of top-notch VCs including Sofinnova Partners and HealthCap (a previous investor in Esperion), who poured in €25 million ($30.5 million) in August 2005.

Esperion Therapeutics Inc. 's $1.25 billion sale to Pfizer Inc. in December 2003 was almost certainly a one-off. [See Deal] The biotech's most developed program was only in Phase II, yet the extraordinary price offered 1400% returns for the average private investor and a 55% premium to an already-high stock price. This is not the kind of deal that happens twice.

Still, when Esperion's ex-VP chemistry and technologies Jean-Louis Dasseux, PhD co-founded Cerenis Therapeutics SA in March 2005, he was...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.